Article

VIDEO: Chandra Osborn, PhD, MPH, Addresses Technologies That Impact Behavioral Outcomes in Diabetes

Conference|ADA: American Diabetes Association

Chandra Osborn, PhD, MPH, addresses the technologies available that impact behavioral outcomes in diabetes, such as mobile devices, PDAs, and the Internet. These technologies can be leveraged to improve self-management behaviors and outcomes in diabetes.

Chandra Osborn, PhD, MPH, addresses the technologies available that impact behavioral outcomes in diabetes, such as mobile devices, PDAs, and the Internet. These technologies can be leveraged to improve self-management behaviors and outcomes in diabetes.

For example, reminder systems can help patients remember to refill prescriptions, perform blood sugar tests, and administer insulin. These systems are a cost-effective method for helping remind patients to perform specific behaviors for a short-time, and should be implemented for newly diagnosed patients to assit them in becoming acclimated to the self-management of their diabetes.

Related Videos
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center (UPMC)
Kimberly Westrich, MA, chief strategy officer, NPC
Marla Black Morgan, MD, Phoebe Neurology Associates
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center (UPMC)
Bridgette Picou, LVN, ACLPN, The Well Project
Laura Bobolts, PharmD, BCOP, senior vice president of clinical strategy and growth at OncoHealth
Adam Colburn, JD, associate vice president for congressional affairs, AMCP
Richard Nowak, MD, MS, Yale School of Medicine
AMCP Recap 2025
Giulio Cossu, MD
Related Content
The consensus guidelines aim to provide practical guidance for institutions administering gene therapy in a commercial or trial setting. | Image credit: CrazyJuke - stock.adobe.com
April 18th 2025

Consensus Guidelines Aim to Optimize DMD Gene Therapy Delivery

Rose McNulty
Multidisciplinary coordination across prescribing teams, nursing, laboratory medicine, finance, and infusion centers is crucial for gene therapy delivery in Duchenne muscular dystrophy (DMD).
Image of Managed Care Cast logo
August 29th 2023

The Importance of Examining and Preventing Atrial Fibrillation

Maggie L. Shaw
At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Myasthenia gravis | Image Credit: © missbobbit-stock.adobe.com
April 18th 2025

Key Indicators of Myasthenia Gravis Disease Progression Reduced With Efgartigimod

Maggie L. Shaw
Research presented at the recent annual meeting of the Academy of Managed Care Pharmacy highlights outcomes among patients who have anti-acetylcholine receptor antibody-positive myasthenia gravis that include reduced exacerbations and need for immunoglobulin.
Managed Care Cast.
June 28th 2022

Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions

Matthew Gavidia
On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
COVID-19 | Image Credit: © blvdone-stock.adobe.com
April 14th 2025

Bias Reduction, Better Access Key to COVID-19 Equity Gains

Maggie L. Shaw
Interventions that target enhancing health care equity among communities disproportionately affected by the COVID-19 pandemic can be improved by including comprehensive needs assessments at the patient, provider, and health system levels.
Orca-T shows promise to reduce rehospitalization and improve outcomes in MDS and acute leukemias.| Image credit: Eleni - stock.adobe.com
April 11th 2025

Reduced Rehospitalizations and Potential Cost Savings With Orca-T for Acute Leukemia, MDS: Caspian Oliai, MD, MS

Mary Caffrey Caspian Oliai, MD, MS Rose McNulty
Orca-T showed lower rates of graft-vs-host disease or infection compared with allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome (MDS) or acute leukemias in the Precision-T trial, Caspian Oliai, MD, MS, UCLA Bone Marrow Transplantation Stem Cell Processing Center, said.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo